IM Cannabis Corp. Reports Sharp Revenue Decline and Deepening Losses in H1 2026
Event summary
- Revenue fell to $16.3M in H1 2026, down from $25.2M in the same period of 2025.
- Net loss widened to $6.9M (or $0.85 per share) compared to a minimal net loss of $0.02M in H1 2025.
- Cash reserves dropped to $1.6M as of June 30, 2026, from $2.7M at the end of 2025.
- Total liabilities exceeded total assets by $5.6M, indicating a shareholders' deficit.
The big picture
IM Cannabis Corp. is facing significant financial headwinds, with revenue and gross profit both halving year-over-year. The company's struggles reflect broader challenges in the medical cannabis sector, including regulatory uncertainties and intense competition. Its ability to pivot into technology-driven sectors or secure additional funding will be critical for long-term viability.
What we're watching
- Profitability Challenges
- Whether IM Cannabis can stabilize its gross margins amid declining revenues and rising costs.
- Cash Flow Management
- The pace at which the company depletes its cash reserves, given its current liabilities and limited liquidity.
- Regulatory Risks
- How geopolitical tensions in Israel and Germany may impact operations and compliance with local regulations.